Loading...
•
Dec 31, 2022
Verve Therapeutics Q4 2022 Earnings Report
Verve Therapeutics reported fourth quarter and full year 2022 financial results, provided pipeline progress, and highlighted the ongoing heart-1 clinical trial of VERVE-101 and preclinical development of VERVE-201.
Key Takeaways
Verve Therapeutics reported a net loss of $41.1 million for the fourth quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $554.8 million as of December 31, 2022, which is expected to fund operations into the second half of 2025.
VERVE-101 clinical trial is ongoing in New Zealand and the UK, with data expected in the second half of 2023.
VERVE-201 is progressing through preclinical development, with clinical initiation anticipated in 2024.
The company is well-capitalized with $554.8 million, supporting runway into the second half of 2025.
Verve plans to present preclinical data from its VERVE-201 program at this year’s American College of Cardiology (ACC) Annual Meeting being held in New Orleans, March 4-6, 2023.
Verve Therapeutics
Verve Therapeutics
Forward Guidance
Verve Therapeutics expects its existing cash, cash equivalents and marketable securities will enable the company to fund its operating expenses and capital expenditure requirements into the second half of 2025.